Completed PHASE3 INTERVENTIONAL 1-arm NCT01104792

Long-term Study of Cariprazine in Patients With Schizophrenia

Evaluation of the Long-term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients With Schizophrenia

Sponsor: Forest Laboratories

Interventions Cariprazine

Updated 8 times since 2017 Last updated: Jul 25, 2019 Started: May 31, 2010 Primary completion: Jan 31, 2013 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Schizophrenia and is currently completed. Forest Laboratories leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Aug 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Aug 2019 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Forest Laboratories
Gedeon Richter Ltd.

Data source: Forest Laboratories

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Arkhangelsk, Russia , Atlanta, United States , Aurangabad, India , Austin, United States , Bellevue, United States , Bello, Colombia , Bogotá, Colombia , Bradenton, United States , Bucharest, Romania and 57 more locations